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012.09.0Abstract Introduction: Acute STEMI is the most serious presentation of CAD. Restoration of the
coronary ﬂow facilitates cardiomyocyte salvage and decreases cardiac morbidity and mortality.
However, reperfusion may result in paradoxical cardiomyocyte dysfunction, a phenomenon termed
reperfusion injury. Trimetazidine is a metabolic anti-ischemic drug which is beneﬁcial in reducing
periprocedural myocardial reperfusion injury.
The aim of the work is to study the effect of trimetazidine on myocardial salvage index in patients
with acute STEMI who underwent primary PCI.
Methods: Forty patients presented with acute STEMI, underwent primary PCI with injection of an
intravenous dose of Tc-99m labeled Sestamibi before primary PCI then ﬁrst set of SPECT images
were taken within 6 h from injection time to assess the initial size of the perfusion defect. Prior to
discharge the patients received another dose of Tc-99m labeled Sestamibi and follow up SPECT
images were taken to assess the ﬁnal perfusion defect and to calculate myocardial salvage and myo-
cardial salvage index.
Twenty patients of them received trimetazidine before primary PCI (study group) and the other
twenty patients did not receive trimetazidine (control group).
Results: (1) Patients with acute STEMI undergoing primary PCI who received trimetazidine before
primary PCI had better myocardial salvage index, however it was statistically non signiﬁcant. (2)
Statistically signiﬁcant better myocardial salvage index with post procedural TIMI 3 ﬂow than with
post procedural TIMI 2 ﬂow among patients who received trimetazidine before primary PCI.
Conclusion: In the presence of post procedural TIMI3 ﬂow trimetazidine is beneﬁcial in improving
myocardial salvage index in patients presented with acute STEMI who underwent primary PCI.
ª 2012 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.om (F. Khaled).
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041. Introduction
ST segment elevation myocardial infarction (STEMI) is the
most serious presentation of atherosclerotic coronary artery
disease carrying the most hazardous consequences and it is
caused by occlusion of major coronary artery.1 Primaryg by Elsevier B.V. All rights reserved.
182 F. Khaled et al.percutaneous coronary intervention (PCI) is the preferred
reperfusion strategy especially when performed by an experi-
enced team within the shortest possible time from ﬁrst medical
contact.2
One of the main aims of all treatment modalities in STEMI
is mortality reduction, and since the use of mortality as an end
point in randomized trials of reperfusion therapy requires
increasingly large sample sizes, there has been a growing inter-
est in assessment of infarct size by technetium (Tc)-99m
Sestamibi single photon emission computed tomography
(SPECT) imaging as a surrogate end point for both early and
late mortality.3 On the basis of the available scientiﬁc evidence,
SPECT imaging with Tc-99m Sestamibi is the best available
measurement tool for infarct size in clinical medicine. Tc-99m
Sestamibi scintigraphy is considered a reliable method to assess
myocardial salvage (difference between the actual and potential
infarct size) achieved by reperfusion therapy.3 Trimetazidine is
a metabolic anti-ischemic drug that exerts its beneﬁcial effects
without altering hemodynamic function of the heart.
It acts by optimizing cardiac metabolism by reducing fatty
acid oxidation through selective inhibition of mitochondrial 3-
ketoacyl coenzyme A thiolase so it decreases ischemic stress
and improves cardiac performance and also it showed cytopro-
tective effect in several models of myocardial infarction.4 Also
trimetazidine is beneﬁcial in reducing peri-procedural myocar-
dial reperfusion injury in elective PCI.5
2. Aim of the work
To assess the effect of trimetazidine on myocardial salvage in-
dex in patients with STEMI undergoing primary PCI.
3. Patients and methods
This study was conducted on forty patients admitted to the
Ain Shams University Hospital by acute STEMI eligible for




All patients were presented with typical rise and/or fall of car-
diac biomarkers of myocardial necrosis with at least one of the
following:
(1) New ST segment elevation at the J point in two contig-
uous leads with cut off points: 0.2 mV in men and
0.15 mV in women in leads V2 and V3 and/or 0.1 mV
in other leads.
(2) Any ischemic symptoms such as chest pain, palpitation
or dyspnea.6 Reperfusion therapy was indicated in
patients who sought medical advice within 12 h of onset
of continuous symptoms, also persistence of ischemic
symptoms after 12 h was considered as an indication
of reperfusion.3.1.2. Exclusion criteria
Patients who had one or more of the following were excluded
from the study:(1) Previous AMI.
(2) Patients with contraindication for primary PCI such as
high risk bleeding as intracranial hemorrhage.
(3) Patients who were hemodynamically unstable or clini-
cally unﬁt to be transferred to myocardial perfusion scan
laboratory.
(4) Previous CABG surgery.
(5) Re-infarction during CCU admission before acquiring
second SPECT image.
Patients were classiﬁed into two groups, group 1 included
twenty patients who received 70 mg of trimetazidine loading
before primary PCI and continued on 70 mg/day in two di-
vided doses till the second SPECT image (study group) and
group 2 included twenty patients who did not receive trimetaz-
idine (control group).
3.2. Methods
All patients were subjected to:
3.2.1. Thorough history taking
Full history was taken from all cases as regards:
1- Personal history: Age, sex, and detailed risk proﬁle as
regards diabetes mellitus, hypertension, dyslipidemia
and smoking status.
2- Past history: Including past history of AMI or prior his-
tory of anginal symptoms or renal impairment.
3- Family history: As regards family history of premature
CAD (men <55 years of age or women <65 years of
age) or occurrence of sudden cardiac death.
4- Presenting complaint: Chest pain was analyzed as
regards duration prior to admission, associated symp-
toms, and presence of angina equivalents.
3.2.2. Full clinical examination
Each patient was thoroughly examined
1- General examination: With special emphasis on vital
data especially arterial blood pressure and heart rate.
2- Local cardiac examination: All patients were subjected
to full cardiac examination stressing on the presence of
mechanical complications and signs of heart failure as:
mitral regurgitation, ventricular septal defects, S3 gallop
and basal rales.
3.2.3. Twelve lead surface ECG
ECG was done to all patients on admission, immediately post
procedure, 90 min after primary PCI and serially every 8 h for
the next 24 h, then daily till discharge. ECG machine was used
to record standard 12-lead ECGs.
3.2.4. Full Labs
Full labs were carried out for all patients on admission and fol-
lowed up thereafter with special emphasis on cardiac enzymes
(CK and CK-MB), renal proﬁle (serum creatinine, sodium,
and potassium) and complete blood count (hemoglobin and
platelet count).
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Echocardiographic assessment was done to each patient prior
to discharge using a GE vivid ﬁve machine to assess ejection
fraction, LV dimensions, presence of segmental wall motion
abnormality, or mechanical complications.
3.2.6. Primary PCI protocol
All cases were given:
(1) Acetyl salicylic acid: All patients were given 300 mg
loading of acetyl salicylic acid and kept on 150 mg daily
thereafter.
(2) Clopidogrel: All patients were given a loading dose of
600 mg clopidogrel prior to procedure, and kept on
75 mg daily thereafter.
(3) Unfractionated heparin: All patients were given 10,000
international units (IU) of unfractionated heparin at
the beginning of intervention and kept on it till dis-
charge with partial thromboplastin time adjusted to
1.5–2 basal.
(4) GP IIb/IIIa inhibitor: Was given at the discretion of treat-
ing physician. Then all patients underwent primary PCI
after diagnostic coronary angiography, the infarct
related artery (IRA) was identiﬁed and treated using bare
metal stents ± pre-dilatation by balloons according to
the discretion of treating physician. After the end of
revascularization TIMI ﬂow grading was calculated.7
3.2.7. SPECT imaging protocol
The patients were given an intravenous dose of Tc-99m labeled
Sestamibi (20–30 mCi) followed by their designated reperfu-
sion therapy via primary intervention then SPECT ﬁrst set of
images were taken within 6 h from the time of injection of
the radioactive material to assess the initial size of the perfu-
sion defect prior to reperfusion (myocardium at risk). With
semi-quantitative visual analysis and displaying the imagesFigure 1 Standard segmental myocardial display for semi-quantita
vascular territory schematic.8using a four dimension (4DM) SPECT, a score was assigned
to represent myocardial perfusion.
A segmentation model has been standardized for this ap-
proach by dividing the myocardium into 17 segments on the
basis of three short-axis slices and a representative long-axis
slice to depict the apex, see Fig. 1. Perfusion was graded within
each segment on a scale of 0–4, with 0 representing normal per-
fusion and four representing a very severe perfusion defect.
Scores for all 17 segments were added to create a summed
score representing myocardium at risk.8 Prior to discharge
the patients received another dose of Tc-99m labeled Sestamibi
(20–30 mCi) and follow up SPECT images were taken to assess
the ﬁnal perfusion defect and to calculate myocardial salvage.
Sum of the 17 segmental scores from the 2nd image repre-
sented the ﬁnal size of infarction. See Figs. 3 and 4. Myocar-
dial salvage is the difference between initial perfusion defect
(myocardium at risk) and ﬁnal perfusion defect (ﬁnal size of
infarction) and myocardial salvage index was obtained from
the following equation.
Initial perfusion defect
 Final infarction size=Initial perfusion defect3.3. Statistical analysis
 Categorical variables were expressed as absolute and
relative frequencies (percentage) while continuous
variables were presented as mean values ± standard
deviation (SD).
 Comparisons were made between the two groups using
t-test for continuous variables and chi-square test and
Pearson correlation coefﬁcient for categorical
variables.
 Statistical analysis was performed using SPSS (statisti-
cal package version sixteen).tive visual analysis in a 17 segment model, with corresponding
Table 1 Comparison between patients who received trimetazidine before primary PCI (group 1) and patients who did not receive
trimetazidine before primary PCI (group 2) as regards age, sex, risk factors for CAD, time to reperfusion, location of myocardial
infarction, and the culprit vessel.
Variable Group 1 Group 2 P value
n= 20 n= 20
Age in years 54.7 ± 9.3 57.8 ± 11.8 P=NS
Mean ± SD
Sex number (%) Female 3 (15%) 2 (10%) P=NS
Male 17 (85%) 18 (90%)
Hypertension number (%) +ve 6 (30%) 8 (40%) P=NS
Diabetes mellitus number (%) +ve 11 (55%) 9 (45%) P=NS
Smoking number (%) +ve 15 (75%) 12 (60%) P=NS
Family history number (%) +ve 1 (5%) 2 (10%) P=NS
Time to reperfusion in hours
Mean ± SD
4.95 ± 3.6 4.96 ± 4.3 P=NS
Location of AMI number (%) Anterior 13 (65%) 11 (55%) P=NS
Non anterior 7 (35%) 9 (45%)
Culprit vessel number (%) LAD 13 (65%) 11 (55%) P=NS
LCX 2 (10%) 2 (10%)
RCA 5 (25%) 7 (35%)
Table 2 Comparison between patients who received trime-
tazidine before primary PCI (group 1) and patients who did not
receive trimetazidine before primary PCI (group 2) as regards







TIMI ﬂow number (%)
TIMI 0 0 (0%) 0 (0%) P=NS
TIMI 1 0 (0%) 0 (0%)
TIMI 2 8 (40%) 11 (55%)
TIMI 3 12 (60%) 9 (45%)
Table 3 Comparison between patients who received trime-
tazidine before primary PCI (group 1) and patients who did not
receive trimetazidine before primary PCI (group 2) as regards
the initial perfusion defect, the ﬁnal perfusion defect and the
myocardial salvage index.
Variable Group 1 Group 2 P value
n= 20 n= 20
Initial perfusion defect
Mean ± SD
27 ± 11.1 27.9 ± 12.3 P=NS
Final perfusion defect
Mean ± SD
18 ± 9.5 22.15 ± 10.10 P=NS
Myocardial salvage index
Mean ± SD
29.71 ± 24.4% 21.43 ± 21.5% P=NS
184 F. Khaled et al. Difference was considered statistically signiﬁcant at a P
value <0.05 and highly signiﬁcant at P value <0.01.
4. Results
According to receiving of trimetazidine patients were divided
into two groups:Study group (1): It included twenty patients who received
trimetazidine before primary PCI.
Control group (2): It included twenty patients who did not
receive trimetazidine before primary PCI. Both groups were
comparable as regards age, sex, risk factors for CAD, time
to reperfusion, location of myocardial infarction and the
culprit vessel as shown in Table 1.
After the end of primary PCI post procedural TIMI
ﬂow grading was done. Although, post procedural TIMI 3
ﬂow was more among the study group (12 vs. 9) yet the
difference was not statistically signiﬁcant as shown in Table 2.
Both groups were compared as regards the initial perfusion
defect, the ﬁnal perfusion defect and the myocardial salvage in-
dex. There was no statistically signiﬁcant difference between
both groups with nearly equal initial perfusion defect
(27 ± 11.1 vs. 27.9 ± 12.3) and smaller ﬁnal perfusion defect
in group 1 than in group 2 (18 ± 9.5 vs. 22.15 ± 10.10) and
better myocardial salvage index in group 1 than in group 2
(29.71 ± 24.4% vs. 21.43 ± 21.5%). These results are shown
in Table 3 and Fig. 2.
An important factor that affects the myocardial salvage in-
dex is post procedural TIMI ﬂow. Myocardial salvage index in
both groups was correlated with post procedural TIMI ﬂow as
shown in Table 4.
Myocardial salvage index was higher in patients with post
procedural TIMI 3 ﬂow than in patients with post procedural
TIMI 2 ﬂow in both groups with statistically signiﬁcant differ-
ence in group 1 receiving trimetazidine before primary PCI
(38.32 ± 26.6% vs. 16.80 ± 13.88%) and non statistically sig-
niﬁcant difference in group 2 who did not receive trimetazidine
before primary PCI (28.09 ± 27.95% vs.15.99 ± 13.44%).
Initial perfusion defect, ﬁnal infarction size and myocardial
salvage index were compared between the two groups in pa-
tients with post procedural TIMI 2 ﬂow, and in patients with
post procedural TIMI three ﬂow. There was nearly equal myo-
cardial salvage index in both groups in patients with post pro-







Initial size of infarction (SSS) Final size  of infarction (RSS)
Study group Control group 
Salvage index%
Figure 2 Comparison between both groups as regards initial size of infarction, ﬁnal size of infarction and myocardial salvage index.
Table 4 Correlation between post procedural TIMI ﬂow and
myocardial salvage index in both groups.
Variable TIMI 2 (%) TIMI 3 (%) P value
Myocardial salvage
index in group 1
Mean ± SD
16.80 ± 13.9 38.32 ± 26.6 P< 0.05
Myocardial salvage
index in group 2
Mean ± SD
16 ± 13.44 28.09 ± 28 P=NS
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did not receive trimetazidine before primary PCI
(16.80 ± 13.9 vs. 15.99 ± 13.44) as shown in Table 5.
Among patients with post procedural TIMI 3 ﬂow in spite
of larger initial perfusion defect (28.5 ± 12.2 vs. 25.11 ± 15.4)
the ﬁnal size of infarction was smaller (16.25 ± 9.6 vs.
17.44 ± 11.5) and myocardial salvage index was higher
(38.32 ± 26.6 vs. 28.09 ± 27.9) in group 1 who received trime-
tazidine before primary PCI than group 2 who did not receive
trimetazidine before primary PCI yet it was not statistically
signiﬁcant as shown in Table 6.
5. Discussion
The primary goal in the management of acute STEMI is to
start reperfusion therapy as early as possible whether mechan-
ical or pharmacological reperfusion.2 Primary PCI according
to the ESC guidelines is the preferred treatment if performed
by an experienced team within 90 min of ﬁrst medical contact
(FMC) or in patients presented by cardiogenic shock and those
with contraindications to ﬁbrinolytic therapy irrespective of
time delay.2 Compared with ﬁbrinolytic therapy, primary
PCI had shown more effective restoration of patency, less re-
occlusion, less bleeding complications, improved residual LV
function and better clinical outcome.9Maintenance of myocardial viability is the goal of reperfu-
sion therapy during AMI. Myocardial salvage, deﬁned as the
amount of myocardium that was jeopardized by a coronary
occlusion but spared from infarction and can be used to com-
pare different treatment options so that strategies that show a
beneﬁt in salvage could be implemented in clinical practice.10
Restoration of the coronary ﬂow facilitates cardiomyocyte
salvage and decreases cardiac morbidity and mortality. How-
ever, reperfusion may result in paradoxical cardiomyocyte dys-
function, a phenomenon termed ‘‘reperfusion injury’’ and this
is observed in all modalities of reperfusion including thrombol-
ysis, PCI, CABG, and cardiac transplantation.20
Trimetazidine is a metabolic anti-ischemic drug which is
beneﬁcial in reducing peri-procedural myocardial reperfusion
injury in elective PCI.5
5.1. Effect of trimetazidine on myocardial salvage
In the present study myocardial salvage was better in the group
who received trimetazidine before primary PCI yet it was not
statistically signiﬁcant. This ﬁnding agrees with Steg and his
colleagues in 2001 who carried out a study on 94 patients with
AMI who were randomized to receive trimetazidine (40 mg bo-
lus followed by 60 mg/day intravenously for 48 h) or placebo,
starting before re-canalization of the infarct vessel by primary
angioplasty and it reported that blinded ST segment analysis
showed that despite higher initial ST deviation from baseline
in the trimetazidine group there was an earlier and more
marked return toward baseline within the ﬁrst 6 h than in
the placebo group. There was a trend toward less frequent
exacerbation of ST deviation at the time of re-canalization in
the trimetazidine group. There was no difference in LV wall
motion at day 14, or in enzymatic infarct size.11 This was con-
cordant too with Dong and his colleagues in 2007 who studied
the effect of trimetazidine as an adjunctive treatment to reper-
fusion therapy in AMI. Sixty patients with AMI were random-
ized to receive trimetazidine (a loading dose of 60 mg followed
by 20 mg 3 times daily) for 2 weeks or to be controls. The
Figure 3 Calculation of the initial and ﬁnal size of infarction in patient number ‘‘16’’ in the study group.
186 F. Khaled et al.loading dose was started early before the reperfusion therapy.
Patients received intermittent ST segment monitoring to assess
the resolution of ST segment deviation one hour after reperfu-
sion therapy. In-hospital and 3-months major adverse cardiac
events were recorded. Blinded ST segment analysis showed
that there was a more marked return toward baseline one hour
after reperfusion therapy in the trimetazidine group, than in
the control group [change (7.14 ± 3.50) vs. (3.79 ±
1.32) mm, P= 0.041].12
There were also several studies that support the cardio-
protective effect of trimetazidine during PCI procedure such
as Polon´ski and his colleagues in 2002 who studied the effect
of pre-treatment with trimetazidine on the degree of ischemiaduring PTCA. Overall 44 patients with one-vessel coronary
artery stenosis (>70%) in the med LAD artery were in-
cluded. One group was pretreated with oral trimetazidine.
The other group was the control. The mean ST segment ele-
vation during all balloon inﬂations was signiﬁcantly lower in
the trimetazidine group than in the control group
(1.66 ± 1.50 vs. 3.29 ± 1.59 mm, P= 0.001). Maximal ST
segment elevations and mean ST elevation values during
sequential balloon inﬂations were also signiﬁcantly lower with
trimetazidine (P= 0.018), and they suggested that trimetazi-
dine administered a few days before PTCA appears to be a
cardio-protective agent for the prevention of myocardial
ischemia.13
Figure 4 The four DM SPECT images of patient number ‘‘16’’ in the study group before and after reperfusion.
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mediators of reperfusion injury as trimetazidine decreases fatty
acid oxidation and stimulates glucose utilization, restoring
coupling between glycolysis and carbohydrate oxidation, and
leads to ATP production with less oxygen consumption and
by stimulating membrane phospholipid turnover during ische-
mia and reperfusion, trimetazidine also redirects fatty acids to-
ward phospholipids.14 This is also supported by Williams and
his colleagues in 1993 who reported that trimetazidine inhibits
neutrophil accumulation without adverse effects on vascular
permeability and protects myocardial cells from reperfusioninjury, attenuates intracellular acidosis during ischemia, and
accelerates restoration of phosphorylation at reperfusion.15
It agrees too with Bonello and his colleagues in 2007 who
studied the beneﬁcial effect of trimetazidine in preventing
ischemia–reperfusion injury by inhibiting mitochondrial ATP
opening, which represents a crucial event in cardiomyocyte
death following ischemia reperfusion.5
It also goes with Kuralay and his colleagues in 2006 who
reported in their study that patients receiving trimetazidine
orally 3 days prior to PTCA had signiﬁcantly decreased level
of C reactive protein, tumor necrosis factor (TNF) a and nitric
Table 5 Comparison of initial perfusion defect, ﬁnal infarc-
tion size and myocardial salvage index between the two groups
in patients with post procedural TIMI 2 ﬂow.
Variable Group 1 Group 2 P value
Initial perfusion defect
Mean ± SD
24.75 ± 9.29 30.18 ± 9.2 P=NS
Final infarction size
Mean ± SD
20.62 ± 9.50 26 ± 9.34
Myocardial salvage index
Mean ± SD
16.80 ± 13.9% 15.99 ± 13.44%
Table 6 Comparison of initial perfusion defect, ﬁnal infarc-
tion size and myocardial salvage index between the two groups
in patients with post procedural TIMI 3 ﬂow.
Group 1 Group 2 P value
Initial perfusion defect
Mean ± SD
28.5 ± 12.2 25.11 ± 15.4 P=NS
Final infarction size
Mean ± SD
16.25 ± 9.6 17.44 ± 11.5
Salvage index
Mean ± SD
38.32 ± 26.6 28.09 ± 27.9
188 F. Khaled et al.oxide during initial 48 h after PTCA and it is known that
PTCA triggers systemic inﬂammatory response by inducing
ischemia reperfusion cycle through repeated balloon inﬂation
which can be followed by tissue injury and impaired anti-oxi-
dant status.16
5.2. Myocardial salvage and TIMI ﬂow
An important factor that affects myocardial salvage is the
TIMI ﬂow. In the current work myocardial salvage index
was higher in both groups in patients with post procedural
TIMI 3 ﬂow than in those with TIMI 2 ﬂow. Among patients
with post procedural TIMI 3 ﬂow better myocardial salvage
index was recorded in group 1 who received trimetazidine yet
it was not statistically signiﬁcant and among patients with post
procedural TIMI 2 ﬂow there was almost equal myocardial
salvage index and these data are supported by Ndrepepa and
his colleagues in 2010 as they reported that restoration of sub-
optimal epicardial ﬂow (TIMI grade 62) denotes increased
segmental coronary resistance due to severe vascular obstruc-
tion and is associated with extensive myocardial necrosis,
reduced myocardial salvage with primary PCI, negative LV
remodeling and increased mortality.17 Only patients with
TIMI 3 ﬂow were deﬁned as having successful reperfusion,
only TIMI 3 ﬂow was associated with improved mortality
and clinical outcome with TIMI 2 ﬂow was comparable to
TIMI 0 or 1 ﬂow.18
Restoration of an optimal epicardial ﬂow is a prerequisite
for restoration of normal reperfusion at the microcirculation
level and the latter is a precondition for unimpeded blood ﬂow
in the epicardial coronary system and none of the patients with
restoration of the suboptimal epicardial ﬂow (TIMI grade 62)
had optimal ﬂow at the microcirculation level of myocardial
blush grade 3 (MBG3), even those with TIMI 3 ﬂow may havea suboptimal myocardial reperfusion at microcirculation le-
vel.19 A ﬁnal important point to note is that the effect of TIMI
ﬂow on myocardial salvage index was very obvious in the
group who received trimetazidine before primary PCI with sta-
tistically signiﬁcant high myocardial salvage index in patients
with post procedural TIMI 3 ﬂow than those with post proce-
dural TIMI 2 ﬂow that could be explained by the fact that in
the presence of optimal epicardial ﬂow and better perfusion on
microcirculation level trimetazidine can exert its cytoprotective
effect on the myocytes with resultant better myocardial salvage
index.
6. Conclusion
Successful reperfusion with primary PCI with restoration of
myocardial blood ﬂow as evident by post procedural TIMI 3
ﬂow, trimetazidine on top of this important factor may be ben-
eﬁcial in minimizing ﬁnal infarction size and improving myo-
cardial salvage index in patients presented with acute STEMI
who underwent primary PCI.
7. Limitations of the study
Our ﬁndings are based on a single-center study with a rela-
tively small sample size of the cohort. Multicenter studies
employing the same protocol and examining a larger number
of patients are further needed.References
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